Neutralization Potential of the Plasma of HIV-1 Infected Indian Patients in the Context of Anti-V3 Antibody Content and Antiretroviral Therapy. [corrected]

Overview

Journal J Microbiol

Specialty Microbiology

Date 2012 Feb 28

PMID 22367950

Citations 6

Authors

Alok Kumar Choudhary

Raiees Andrabi

Somi Sankaran Prakash

Rajesh Kumar

Shubhasree Dutta Choudhury

Naveet Wig

Ashutosh Biswas

Anjali Hazarika

Kalpana Luthra

Affiliations

Soon will be listed here.

Abstract

We assessed the anti-V3 antibody content and viral neutralization potential of the plasma of 63 HIV-1-infected patients (antiretroviral naïve=39, treated=24) against four primary isolates (PIs) of clade C and a tier 1 clade B isolate SF162. Depletion and inhibition of anti-V3 antibodies in the plasma of five patients with high titers of anti-V3 antibodies led to modest change in the neutralization percentage against two PIs (range 0-21%). The plasma of antiretroviral-treated patients exhibited higher neutralization potential than that of the drug-naïve plasmas against the four PIs tested which was further evidenced by a follow-up study.

Citing Articles

CD4-Binding Site Directed Cross-Neutralizing scFv Monoclonals from HIV-1 Subtype C Infected Indian Children.

Kumar S, Kumar R, Khan L, Makhdoomi M, Thiruvengadam R, Mohata M Front Immunol. 2017; 8:1568.

PMID: 29187855 PMC: 5694743. DOI: 10.3389/fimmu.2017.01568.

Broad and potent cross clade neutralizing antibodies with multiple specificities in the plasma of HIV-1 subtype C infected individuals.

Cheedarla N, Lucia Precilla K, Babu H, Vijayan K, Ashokkumar M, Chandrasekaran P Sci Rep. 2017; 7:46557.

PMID: 28436427 PMC: 5402285. DOI: 10.1038/srep46557.

Cross-neutralizing anti-HIV-1 human single chain variable fragments(scFvs) against CD4 binding site and N332 glycan identified from a recombinant phage library.

Khan L, Kumar R, Thiruvengadam R, Parray H, Makhdoomi M, Kumar S Sci Rep. 2017; 7:45163.

PMID: 28332627 PMC: 5362912. DOI: 10.1038/srep45163.

A recombinant adenovirus-based vector elicits a specific humoral immune response against the V3 loop of HIV-1 gp120 in mice through the "Antigen Capsid-Incorporation" strategy.

Gu L, Krendelchtchikova V, Krendelchtchikov A, Oster R, Fujihashi K, Matthews Q Virol J. 2014; 11:112.

PMID: 24935650 PMC: 4065546. DOI: 10.1186/1743-422X-11-112.

Highly efficient neutralization by plasma antibodies from human immunodeficiency virus type-1 infected individuals on antiretroviral drug therapy.

Andrabi R, Makhdoomi M, Kumar R, Bala M, Parray H, Gupta A J Clin Immunol. 2014; 34(4):504-13.

PMID: 24682667 DOI: 10.1007/s10875-014-0010-y.

References

Dreyer K, Kallas E, Planelles V, Montefiori D, McDermott M, Hasan M . Primary isolate neutralization by HIV type 1-infected patient sera in the era of highly active antiretroviral therapy. AIDS Res Hum Retroviruses. 1999; 15(17):1563-71. DOI: 10.1089/088922299309856. View

Lakhashe S, Kulkarni S, Thakar M, Ghate M, Paranjape R . Extensive cross-reactive neutralizing antibody response in Indian patients with limited genetic diversity of HIV-1. Virology. 2006; 359(2):295-301. DOI: 10.1016/j.virol.2006.09.019. View

Morris L, Binley J, Clas B, Bonhoeffer S, Astill T, Kost R . HIV-1 antigen-specific and -nonspecific B cell responses are sensitive to combination antiretroviral therapy. J Exp Med. 1998; 188(2):233-45. PMC: 2212446. DOI: 10.1084/jem.188.2.233. View

Richman D, Wrin T, Little S, Petropoulos C . Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc Natl Acad Sci U S A. 2003; 100(7):4144-9. PMC: 153062. DOI: 10.1073/pnas.0630530100. View

Spenlehauer C, Saragosti S, Fleury H, KIRN A, Aubertin A, Moog C . Study of the V3 loop as a target epitope for antibodies involved in the neutralization of primary isolates versus T-cell-line-adapted strains of human immunodeficiency virus type 1. J Virol. 1998; 72(12):9855-64. PMC: 110497. DOI: 10.1128/JVI.72.12.9855-9864.1998. View

Zolla-Pazner S, Cohen S, Krachmarov C, Wang S, Pinter A, Lu S . Focusing the immune response on the V3 loop, a neutralizing epitope of the HIV-1 gp120 envelope. Virology. 2007; 372(2):233-46. DOI: 10.1016/j.virol.2007.09.024. View

Schuitemaker H, Kootstra N . Isolation, propagation, and titration of human immunodeficiency virus type 1 from peripheral blood of infected individuals. Methods Mol Biol. 2005; 304:17-24. DOI: 10.1385/1-59259-907-9:017. View

Fouts T, Binley J, Trkola A, Robinson J, Moore J . Neutralization of the human immunodeficiency virus type 1 primary isolate JR-FL by human monoclonal antibodies correlates with antibody binding to the oligomeric form of the envelope glycoprotein complex. J Virol. 1997; 71(4):2779-85. PMC: 191401. DOI: 10.1128/JVI.71.4.2779-2785.1997. View

Stanfield R, Gorny M, Zolla-Pazner S, Wilson I . Crystal structures of human immunodeficiency virus type 1 (HIV-1) neutralizing antibody 2219 in complex with three different V3 peptides reveal a new binding mode for HIV-1 cross-reactivity. J Virol. 2006; 80(12):6093-105. PMC: 1472588. DOI: 10.1128/JVI.00205-06. View

10.

Wei X, Decker J, Wang S, Hui H, Kappes J, Wu X . Antibody neutralization and escape by HIV-1. Nature. 2003; 422(6929):307-12. DOI: 10.1038/nature01470. View

11.

Kulkarni S, Tripathy S, Gangakhedkar R, Jadhav S, Agnihotri K, Sane S . Neutralizing antibody responses in recent seroconverters with HIV-1 subtype C infections in India. AIDS Res Hum Retroviruses. 2008; 24(9):1159-66. PMC: 2928029. DOI: 10.1089/aid.2007.0296. View

12.

Huang C, Tang M, Zhang M, Majeed S, Montabana E, Stanfield R . Structure of a V3-containing HIV-1 gp120 core. Science. 2005; 310(5750):1025-8. PMC: 2408531. DOI: 10.1126/science.1118398. View

13.

Sahin G, Bowles E, Parker J, Uchtenhagen H, Sheik-Khalil E, Taylor S . Generation of neutralizing antibodies and divergence of SIVmac239 in cynomolgus macaques following short-term early antiretroviral therapy. PLoS Pathog. 2010; 6(9):e1001084. PMC: 2932721. DOI: 10.1371/journal.ppat.1001084. View

14.

Parren P, Burton D, Sattentau Q . HIV-1 antibody--debris or virion?. Nat Med. 1997; 3(4):366-7. DOI: 10.1038/nm0497-366d. View

15.

Frost S, Wrin T, Smith D, Kosakovsky Pond S, Liu Y, Paxinos E . Neutralizing antibody responses drive the evolution of human immunodeficiency virus type 1 envelope during recent HIV infection. Proc Natl Acad Sci U S A. 2005; 102(51):18514-9. PMC: 1310509. DOI: 10.1073/pnas.0504658102. View

16.

Nandi A, Lavine C, Wang P, Lipchina I, Goepfert P, Shaw G . Epitopes for broad and potent neutralizing antibody responses during chronic infection with human immunodeficiency virus type 1. Virology. 2009; 396(2):339-48. PMC: 2789835. DOI: 10.1016/j.virol.2009.10.044. View

17.

Sarmati L, Nicastri E, Ventura L, Salanitro A, Ercoli L, Vella S . Increase in neutralizing antibody titer against sequential autologous HIV-1 isolates after 16 weeks saquinavir (Invirase) treatment. J Med Virol. 1998; 53(4):313-8. View

18.

Kim J, Mascola J, Ratto-Kim S, Vancott T, Cox J, Michael N . Selective increases in HIV-specific neutralizing antibody and partial reconstitution of cellular immune responses during prolonged, successful drug therapy of HIV infection. AIDS Res Hum Retroviruses. 2001; 17(11):1021-34. DOI: 10.1089/088922201300343708. View

19.

Li M, Gao F, Mascola J, Stamatatos L, Polonis V, Koutsoukos M . Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J Virol. 2005; 79(16):10108-25. PMC: 1182643. DOI: 10.1128/JVI.79.16.10108-10125.2005. View